J Sollier, KA Cimprich - Trends in cell biology, 2015 - cell.com
R-loops, nucleic acid structures consisting of an RNA–DNA hybrid and displaced single- stranded (ss) DNA, are ubiquitous in organisms from bacteria to mammals. First described in …
SM Aukema, R Siebert, ED Schuuring… - Blood, The Journal …, 2011 - ashpublications.org
In many B-cell lymphomas, chromosomal translocations are biologic and diagnostic hallmarks of disease. An intriguing subset is formed by the so-called double-hit (DH) …
Burkitt lymphoma is a mature aggressive B-cell lymphoma derived from germinal center B cells. Its cytogenetic hallmark is the Burkitt translocation t (8; 14)(q24; q32) and its variants …
NA Johnson, KJ Savage, O Ludkovski… - Blood, The Journal …, 2009 - ashpublications.org
BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2+/MYC+) were identified in 54 samples by karyotype and/or …
L Nguyen, P Papenhausen, H Shao - Genes, 2017 - mdpi.com
c-MYC is one of the most essential transcriptional factors, regulating a diverse array of cellular functions, including proliferation, growth, and apoptosis. Dysregulation of c-MYC is …
S Sander, DP Calado, L Srinivasan, K Köchert… - Cancer cell, 2012 - cell.com
In Burkitt lymphoma (BL), a germinal center B-cell-derived tumor, the pro-apoptotic properties of c-MYC must be counterbalanced. Predicting that survival signals would be …
M Snuderl, OK Kolman, YB Chen, JJ Hsu… - The American journal …, 2010 - journals.lww.com
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as “double-hit” lymphomas (DHL), are rare neoplasms characterized by highly aggressive …
C López, K Kleinheinz, SM Aukema, M Rohde… - Nature …, 2019 - nature.com
Burkitt lymphoma (BL) is the most common B-cell lymphoma in children. Within the International Cancer Genome Consortium (ICGC), we performed whole genome and …
SH Swerdlow - Hematology 2014, the American Society of …, 2014 - ashpublications.org
Identification of large B-cell lymphomas that are “extra-aggressive” and may require therapy other than that used for diffuse large B-cell lymphoma, not otherwise specified (DLBCL …